Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning

Summary

This is a Phase Ib Pilot study of anti-PSMA designer T cells in metastatic prostate cancer. Subjects will receive escalating doses of T cells, with either low or moderate dose Interleukin 2. The T cells are collected by pheresis and then genetically modified, and given in a one time infusion.

Timeline

Start

2006-03

Primary completion

2017-12

Completion

2018-12

Outcome

Outcome not reported

Stopped (Business): “Funding”

Drugs

Indications

No indication recorded.